Pharmacokinetic-pharmacodynamic modelling of behavioural responses

被引:10
|
作者
Della Paschoa, OE
Kruk, MR
Danhof, M
机构
[1] Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands
[2] Leiden Amsterdam Ctr Drug Res, Div Med Pharmacol, Ethopharmacol Grp, NL-2300 RA Leiden, Netherlands
来源
关键词
PK/PD modelling; behavioural measures; data acquisition; ethopharmacology; ultrasonic vocalizations; buspirone; concentration-effect relationship;
D O I
10.1016/S0149-7634(98)00023-2
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Drug concentrations at the site of action in studies on behavioural pharmacology, are seldom constant. Therefore, observed changes in behaviour can be due to the natural time course of behavioural processes, but equally to changes in drug concentration, and it is therefore crucial to separate the former from the latter. One solution is keeping drug concentrations constant. However, one can also exploit the variation in drug concentration caused by absorption, distribution and elimination of a drug. This is done by simultaneous measurement of drug effect and concentration, while the drug enters and leaves a biologically relevant compartment, such as blood or cerebrospinal fluid. The concept of determining concentration-effect curves in individual animals, by monitoring in parallel drug effect and changes in concentration in one single experiment, has not yet found wide application in behavioural studies. The fact that behavioural processes, like any other physiological process, change over time, may have contributed to the scarcity of pharmacokinetic-pharmacodynamic (PK/PD) studies in behavioural pharmacology. However, there are now mathematical techniques that allow PK/PD modelling even if the effect parameter changes over time or cannot be properly assessed in every instance. Here we use PK/PD modelling to characterize fear-induced ultrasonic vocalizations and the anxiolytic effect of buspirone. This approach reduces the number of animals required to assess concentration-effect relationships. More importantly, it allows the identification of differences in individual drug response over a wide range of concentrations. Consequently, we suggest that PK/PD modelling can be used as a tool to study drug-induced changes in behavioural response. An introduction in PK/PD modelling is presented. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:229 / 236
页数:8
相关论文
共 50 条
  • [1] Pharmacokinetic-pharmacodynamic modelling in anaesthesia
    Gambus, Pedro L.
    Troconiz, Inaki F.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (01) : 72 - 84
  • [2] Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys
    Haritova, A. M.
    Rusenova, N. V.
    Parvanov, P. R.
    Lashev, L. D.
    Fink-Gremmels, J.
    VETERINARY RESEARCH COMMUNICATIONS, 2006, 30 (07) : 775 - 789
  • [3] Pharmacokinetic-pharmacodynamic modelling: History and perspectives
    Csajka, Chantal
    Verotta, Davide
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) : 227 - 279
  • [4] Methodological issues in pharmacokinetic-pharmacodynamic modelling
    Bellissant, E
    Sébille, V
    Paintaud, G
    CLINICAL PHARMACOKINETICS, 1998, 35 (02) : 151 - 166
  • [5] Pharmacokinetic-Pharmacodynamic Modelling of Danofloxacin in Turkeys
    A. M. Haritova
    N. V. Rusenova
    P. R. Parvanov
    L. D. Lashev
    J. Fink-Gremmels
    Veterinary Research Communications, 2006, 30 : 775 - 789
  • [6] Application of microdialysis for pharmacokinetic-pharmacodynamic modelling
    Hoecht, Christian
    Opezzo, Javier A. W.
    Bramuglia, Guillermo F.
    Taira, Carlos A.
    EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (04) : 289 - 301
  • [7] Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling
    Colburn, WA
    Lee, JW
    CLINICAL PHARMACOKINETICS, 2003, 42 (12) : 997 - 1022
  • [8] Biomarkers, Validation and Pharmacokinetic-Pharmacodynamic Modelling
    Wayne A. Colburn
    Jean W. Lee
    Clinical Pharmacokinetics, 2003, 42 : 997 - 1022
  • [9] Methodological Issues in Pharmacokinetic-Pharmacodynamic Modelling
    Eric Bellissant
    Véronique Sébille
    Gilles Paintaud
    Clinical Pharmacokinetics, 1998, 35 : 151 - 166
  • [10] Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine
    Hoshen, MB
    Stein, WD
    Ginsburg, HD
    PARASITOLOGY, 2001, 123 : 337 - 346